Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 100
- Registration Number
- NCT01272128
- Locations
- 🇧🇪
Research Site, Liège, Belgium
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Ocrelizumab-matching placeboDrug: Interferon beta-1a-matching placebo
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 821
- Registration Number
- NCT01247324
- Locations
- 🇺🇸
Northwestern University; Dept. of Neurology, Chicago, Illinois, United States
🇺🇸The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Uni of Vermont Medical Center;, Burlington, Vermont, United States
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 307
- Registration Number
- NCT01207648
- Locations
- 🇻🇪
Research Site, Maracaibo, Venezuela
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
- Conditions
- Multiple Sclerosis, Relapsing, Remitting
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 79
- Registration Number
- NCT01201343
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 129
- Registration Number
- NCT01198132
- Locations
- 🇫🇷
CHU Hôpital Gui de Chauliac Service de Neurologie B, Montpellier, France
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT01181115
- Locations
- 🇨🇳
Research Site, Xi'an, China
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 403
- Registration Number
- NCT01142492
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 86
- Registration Number
- NCT01142518
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 231
- Registration Number
- NCT01142453
Comparing Efficacy and Safety of Inhaled SNG001 to Placebo
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT01126177
- Locations
- 🇬🇧
Southampton University General Hospital, Southampton, Hampshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.